TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION AMONG ADULTS WITH MIGRAINE IN A COMMERCIALLY INSURED US POPULATION (IFORM-II)
Author(s)
Dannielle Lebovitch, MPH1, Cynthia Gutierrez, M.D., MBA1, Earl Burrell, PhD1, Syvart Dennen, PhD1, Jonathan Bouchard, MS, RPh2;
1Genesis Research Group, Hoboken, NJ, USA, 2Ipsen, Cambridge, MA, USA
1Genesis Research Group, Hoboken, NJ, USA, 2Ipsen, Cambridge, MA, USA
OBJECTIVES: This study aims to develop an understanding of the current treatment landscape for incident migraine patients, including treatment patterns, and evaluate healthcare resource utilization (HCRU) and costs in this US population.
METHODS: A non-interventional, retrospective analysis of MarketScan claims data was performed for patients with migraine in the US from July 1, 2019 through June 30, 2022. Eligible patients were aged ≥18 years, had ≥1 confirmed ICD-10 diagnosis code for migraine during the identification period (index date), and continuous enrollment for 12 months before index (pre-index/baseline) through 24 months post-index (follow-up). Patients were excluded if they had evidence of an ICD-10 diagnosis code for migraine or prescriptions/treatments for certain medications including calcitonin gene-related peptides/gepant and triptans during the pre-index period. Patient demographics, clinical characteristics, HCRU, costs, and treatment patterns were assessed.
RESULTS: Overall, 213,158 patients were included for analysis. Patients had a mean (SD) age at index of 42 (14) years and 78% were female. The most commonly used pharmacotherapies during follow-up were prescription nonsteroidal anti-inflammatory drugs (NSAIDs, 49%), opioids/opioid combinations (38%), and triptans (32%); 20% of patients were not receiving migraine treatment. NSAIDs were the most common therapy included in first line (47% of N=169,539), second line (49% of N=102,768), and third line (47% of N=40,814) treatment regimens, followed by triptans and opioids/opioid combinations. Persistence and adherence measurements varied across therapies. The per patient median (quartile [Q]1, Q3) number of migraine prescription fills was 3 (1, 9); cost was $21 ($1, $133). Median (Q1, Q3) total healthcare cost per patient was $9,113 ($3,864, $21,940).
CONCLUSIONS: This study highlights the current treatment landscape for migraine and its considerable impact on HCRU and costs, underscoring the need for optimized treatment strategies.
METHODS: A non-interventional, retrospective analysis of MarketScan claims data was performed for patients with migraine in the US from July 1, 2019 through June 30, 2022. Eligible patients were aged ≥18 years, had ≥1 confirmed ICD-10 diagnosis code for migraine during the identification period (index date), and continuous enrollment for 12 months before index (pre-index/baseline) through 24 months post-index (follow-up). Patients were excluded if they had evidence of an ICD-10 diagnosis code for migraine or prescriptions/treatments for certain medications including calcitonin gene-related peptides/gepant and triptans during the pre-index period. Patient demographics, clinical characteristics, HCRU, costs, and treatment patterns were assessed.
RESULTS: Overall, 213,158 patients were included for analysis. Patients had a mean (SD) age at index of 42 (14) years and 78% were female. The most commonly used pharmacotherapies during follow-up were prescription nonsteroidal anti-inflammatory drugs (NSAIDs, 49%), opioids/opioid combinations (38%), and triptans (32%); 20% of patients were not receiving migraine treatment. NSAIDs were the most common therapy included in first line (47% of N=169,539), second line (49% of N=102,768), and third line (47% of N=40,814) treatment regimens, followed by triptans and opioids/opioid combinations. Persistence and adherence measurements varied across therapies. The per patient median (quartile [Q]1, Q3) number of migraine prescription fills was 3 (1, 9); cost was $21 ($1, $133). Median (Q1, Q3) total healthcare cost per patient was $9,113 ($3,864, $21,940).
CONCLUSIONS: This study highlights the current treatment landscape for migraine and its considerable impact on HCRU and costs, underscoring the need for optimized treatment strategies.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE350
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Neurological Disorders